- Home
- TLSI vs MPA Comparison
TLSI vs MPA Comparison
Compare TLSI & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- MPA
- Stock Information
- Founded
- TLSI 2010
- MPA 1992
- Country
- TLSI United States
- MPA United States
- Employees
- TLSI N/A
- MPA N/A
- Industry
- TLSI Medical Specialities
- MPA Finance Companies
- Sector
- TLSI Health Care
- MPA Finance
- Exchange
- TLSI Nasdaq
- MPA Nasdaq
- Market Cap
- TLSI 204.0M
- MPA 139.0M
- IPO Year
- TLSI N/A
- MPA N/A
- Fundamental
- Price
- TLSI $5.07
- MPA $10.78
- Analyst Decision
- TLSI Strong Buy
- MPA
- Analyst Count
- TLSI 5
- MPA 0
- Target Price
- TLSI $10.90
- MPA N/A
- AVG Volume (30 Days)
- TLSI 154.9K
- MPA 25.2K
- Earning Date
- TLSI 08-13-2025
- MPA 01-01-0001
- Dividend Yield
- TLSI N/A
- MPA 3.83%
- EPS Growth
- TLSI N/A
- MPA N/A
- EPS
- TLSI N/A
- MPA N/A
- Revenue
- TLSI $32,141,000.00
- MPA N/A
- Revenue This Year
- TLSI $55.52
- MPA N/A
- Revenue Next Year
- TLSI $54.76
- MPA N/A
- P/E Ratio
- TLSI N/A
- MPA N/A
- Revenue Growth
- TLSI 46.20
- MPA N/A
- 52 Week Low
- TLSI $3.50
- MPA $9.87
- 52 Week High
- TLSI $6.04
- MPA $12.21
- Technical
- Relative Strength Index (RSI)
- TLSI 45.72
- MPA 50.00
- Support Level
- TLSI $4.81
- MPA $10.74
- Resistance Level
- TLSI $5.63
- MPA $10.87
- Average True Range (ATR)
- TLSI 0.35
- MPA 0.08
- MACD
- TLSI -0.03
- MPA 0.01
- Stochastic Oscillator
- TLSI 30.95
- MPA 59.09
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.